Balt’s Squid liquid embolic receives US FDA approval for adjunctive treatment for chronic subdural hematomas: Boston Friday, February 6, 2026, 17:00 Hrs [IST] Balt Inc, a global ...

Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid(TM) liquid embolic agent. Squid is approved for the embolization of the ...

Kanagawa Gov. Yuji Kuroiwa was hospitalized Tuesday and underwent surgery the following day for chronic subdural hematoma, ...

Yokohama, Feb. 5 (Jiji Press)--Kanagawa Governor Yuji Kuroiwa was hospitalized Tuesday and underwent surgery the following ...

Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid liquid embolic agent. Squid is approved ...

1 Scruton TJ. Updates on the diagnosis and management of subdural hematoma. JAAPA. 2024;37(8):9-15. 2 McBride W. Subdural hematoma in adults: Etiology, clinical features, and diagnosis. Waltham: ...

Earlier this month, Medtronic received a new approval from the FDA for its decades-old liquid embolic system, extending its use to treat certain kinds of internal brain bleeds. Now, Johnson & Johnson ...

- TRUFILL n-BCA is now indicated for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and Chronic Subdural Hematoma (cSDH) as an adjunct to surgery. - ...

Johnson & Johnson has secured an expanded indication from FDA for its TRUFILL n‑BCA Liquid Embolic System for embolization of the middle meningeal artery for the treatment of symptomatic subacute and ...

Despite a rising public health burden, there have been few population-based studies of chronic subdural hematomas (cSDH) in the United States. We provide the first estimates of cSDH incidence and ...